GRI Bio (NASDAQ:GRI) Price Target Raised to $36.00

GRI Bio (NASDAQ:GRI) had its price objective increased by Ascendiant Capital Markets from $35.00 to $36.00 in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GRI Bio in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, GRI Bio currently has an average rating of “Hold” and an average price target of $23.00.

GRI Bio Stock Performance

Shares of NASDAQ GRI opened at $1.21 on Monday. The firm has a fifty day moving average of $1.87 and a 200 day moving average of $1.67. The firm has a market cap of $3.96 million, a PE ratio of -0.14 and a beta of -1.48. GRI Bio has a one year low of $1.10 and a one year high of $16.92.

GRI Bio (NASDAQ:GRI) last posted its quarterly earnings data on Friday, November 14th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.17). On average, equities analysts predict that GRI Bio will post -3.04 EPS for the current fiscal year.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.